Giuseppe Toffoli
Overview
Explore the profile of Giuseppe Toffoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
3227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ius T, Polano M, Dal Bo M, Bagatto D, Bertani V, Gentilini D, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075605
Glioma Grade 4 (GG4) tumors, which include both IDH-mutated and IDH wild-type astrocytomas, are the most prevalent and aggressive form of primary brain tumor. Radiomics is gaining ground in neuro-oncology....
2.
Capolla S, Rasool M, Toffoli G, Dal Bo M
Cancer Med
. 2025 Feb;
14(5):e70726.
PMID: 40013750
Cell therapy based on chimeric antigen receptor (CAR) T cells has represented a revolutionary new approach for treating tumors, especially hematological diseases. Complete remission rates (CRR) > 80%-97% and 50%-90%...
3.
Orleni M, Gagno S, Cecchin E, Montico M, Buonadonna A, Fumagalli A, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2025 Feb;
1255:124526.
PMID: 39985852
Therapeutic drug monitoring during imatinib treatment is recommended to optimize patient clinical outcomes. This study aimed to develop a novel LC-MS/MS method to quantitate imatinib and its active metabolite N-desmethyl-imatinib,...
4.
Mossenta M, Argenziano M, Capolla S, Busato D, Durigutto P, Mangogna A, et al.
Nanomedicine (Lond)
. 2025 Jan;
20(3):255-270.
PMID: 39815170
Background: Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting...
5.
Bozzer S, Grimaldi M, De Maso L, Manfredi M, Toffoli G, Dal Bo M, et al.
Int J Nanomedicine
. 2024 Dec;
19:13267-13286.
PMID: 39679253
Purpose: In the bloodstream, nanoparticles (NPs) interact with serum proteins to form the protein corona, which includes both opsonins, promoting NP recognition and elimination, and dysopsonins, which can inhibit opsonin...
6.
Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2449441.
PMID: 39641926
Importance: To date, the clinical benefit and utility of implementing a DPYD/UGT1A1 pharmacogenetic-informed therapy with fluoropyrimidines and/or irinotecan have not been prospectively investigated. Objective: To examine clinically relevant toxic effects,...
7.
Di Cintio F, Argenziano M, Scomparin A, Capolla S, Busato D, Steffe A, et al.
Nanomedicine (Lond)
. 2024 Dec;
20(1):23-36.
PMID: 39620421
Background: Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target for glioblastoma multiforme (GBM) treatment being specifically...
8.
Gagno S, Posocco B, Orleni M, Cecchin E, Fumagalli A, Guardascione M, et al.
Front Immunol
. 2024 Oct;
15:1441620.
PMID: 39445010
Introduction: Inflammatory factors released during severe coronavirus disease-19 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are known to influence drug exposure, but data on the effect of mild...
9.
Cecchin E, Orleni M, Gagno S, Montico M, Peruzzi E, Roncato R, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408783
Therapeutic drug monitoring (TDM) may be beneficial for cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), such as palbociclib, ribociclib, and abemaciclib, due to established exposure-toxicity relationships and the potential for monitoring treatment...
10.
Peruzzi E, Posocco B, Gerratana L, Nuti M, Orleni M, Gagno S, et al.
Front Pharmacol
. 2024 Sep;
15:1420174.
PMID: 39309010
Palbociclib, an oral inhibitor of cyclin-dependent kinase 4 and 6, is approved for the treatment of metastatic breast cancer. This study investigated the influence of diverse clinical and biological factors-age,...